Review
Immunology
Balakarthikeyan Janani, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi, Mohammed Alsaidan, Nasraddin Othman Bahakim, Mohammad Hassan Abdelzaher, Thiyagarajan Ramesh
Summary: Colorectal carcinoma is a common and lethal form of cancer, with a high rate of metastasis. Targeted nanotherapy, particularly targeting EGFR, has the potential to improve surgical control and reduce tumor-related mortality. Antibodies conjugated with drug-loaded carriers can increase drug effectiveness and quantity delivered to the target site.
Article
Oncology
Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li, Yuesheng Zhang
Summary: Resistance to EGFR inhibitors in colorectal cancer is primarily due to the inability of the inhibitors to downregulate their target. The combination treatment with PEPDG278D overcomes this resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Cell Biology
Hong Lu, Hao Zhang, Mei-lin Weng, Jin Zhang, Nan Jiang, Juan P. Cata, Duan Ma, Wan-Kun Chen, Chang-Hong Miao
Summary: Morphine treatment can activate MOR and promote proliferation, migration, and invasion in CRC cells, as well as increase resistance to cetuximab. It induces EGFR transactivation, leading to protumoral effects in CRC cell lines.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Dongshao Chen, Ruoxi Hong, Youjun Cao, Qingnan Wu, Yan Wang, Jie Chen, Jinting Li, Weimin Zhang, Qimin Zhan
Summary: This study found that dual blockage of EGFR and Wee1 inhibited tumor growth in ESCC partially through PI3K/Akt or MAPK pathway blockade and inducing apoptosis. Meanwhile, the POLR2A might be candidate molecule of EGFR/Wee1 downstream.
Article
Pharmacology & Pharmacy
Yu-Wei Lin, Hung-Cheng Su, Emmanuel Naveen Raj, Kuang-Kai Liu, Chien-Jen Chang, Tzu-Chia Hsu, Po-Yun Cheng, Rou-Hsin Wang, Yen-Her Lai, Chien-Hung Chen, Yen-Cheng Lin, Jui- Chao
Summary: Nanoprobes provide advantages for real-time monitoring of tumor markers and tumorigenesis during cancer progression and development. In this study, a carbon-based nanoprobe, nanodiamond (ND), is used for targeting EGFR and monitoring tumorigenesis of human lung cancer cells in vitro and in vivo. The results show that ND-conjugated specific EGFR antibody cetuximab (Cet) can track the location and distribution of EGFR proteins and increase cellular uptake ability of nanocomposites in EGFR-expressed cells.
Article
Multidisciplinary Sciences
Shen Zhao, Wu Zhuang, Baohui Han, Zhengbo Song, Wei Guo, Feng Luo, Lin Wu, Yi Hu, Huijuan Wang, Xiaorong Dong, Da Jiang, Mingxia Wang, Liyun Miao, Qian Wang, Junping Zhang, Zhenming Fu, Yihua Huang, Chunwei Xu, Longyu Hu, Lei Li, Rong Hu, Yang Yang, Mengke Li, Xiugao Yang, Li Zhang, Yan Huang, Wenfeng Fang
Summary: This study reports the safety and preliminary efficacy of a phase I clinical trial (JMT101) combining an anti-EGFR antibody with EGFR-TKI in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions. The combination therapy demonstrated good tolerability and promising efficacy in patients.
NATURE COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Maochao Luo, Zhao Huang, Xingyue Yang, Yan Chen, Jingwen Jiang, Lu Zhang, Li Zhou, Siyuan Qin, Ping Jin, Shuyue Fu, Liyuan Peng, Bowen Li, Yongting Fang, Wenchen Pu, Yanqiu Gong, Yu Liu, Zhixiang Ren, Qiu-Luo Liu, Cun Wang, Fangqiong Xiao, Du He, Hongying Zhang, Changlong Li, Heng Xu, Lunzhi Dai, Yong Peng, Zong-Gung Zhou, Canhua Huang, Hai-Ning Chen
Summary: This study identifies PHLDB2 as a key player in latent liver metastasis of colorectal cancer (CRC). Chemotherapeutic-induced oxidative stress promotes N6-methyladenosine modification of PHLDB2 messenger RNA, leading to increased protein expression of PHLDB2. Upregulated PHLDB2 stabilizes EGFR and promotes its nuclear translocation, resulting in activation of EGFR signaling and resistance to cetuximab. The study proposes PHLDB2 as a potential target for CRC treatment.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Chemistry, Physical
Lucas Noboru Fatori Trevizan, Josimar O. Eloy, Marcela Tavares Luiz, Raquel Petrilli, Sergio Luiz Ramos Junior, Julio Cesar Borges, Juliana Maldonado Marchetti, Marlus Chorilli
Summary: Liquid crystalline nanodispersions loaded with cetuximab have excellent bioavailability and cytotoxicity, showing better therapeutic effects on prostate cancer cells.
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
(2021)
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Oncology
Jie Qi, Guangsen Xu, Xiaoxia Wu, Chunhua Lu, Yuemao Shen, Baobing Zhao
Summary: Pellino-1 (PELI1), an E3 ubiquitin ligase, plays important roles in inflammation and autoimmunity regulation, as well as promoting tumorigenesis and metastasis. This study uncovered a novel regulation mechanism of PELI1 and EGFR in breast cancer metastasis. EGFR positively correlates with PELI1 expression in breast cancers, and its activation leads to the phosphorylation of PELI1, which activates its E3 ubiquitin ligase function. PELI1 also physically interacts with and stabilizes EGFR through K63-linked polyubiquitination. Co-inhibition of PELI1 and EGFR shows a synergistic effect in repressing breast cancer metastasis, and a compound called S62 effectively disrupts PELI1/EGFR and inhibits breast cancer metastasis.
Article
Oncology
Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Summary: This study investigates the dynamic changes in circulating tumor DNA (ctDNA) as an early indicator of treatment outcome. The results show that complete clearance of mutant EGFR ctDNA at 8 weeks is highly and significantly predictive of decreased risk of progression and death in patients with EGFR mutation tissue-positive non-small cell lung cancer.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Morena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Fernando Paragliola, Francesca Sparano, Maria Lucia Iacovino, Anna Castrichino, Francesca Doria, Antonello Sica, Floriana Morgillo, Giuseppe Colella, Giampaolo Tartaro, Salvatore Cappabianca, Domenico Testa, Gaetano Motta, Fortunato Ciardiello
Summary: Head and neck cancers are the seventh most common cancer worldwide, with squamous cell carcinomas being the most frequent histologic subtype. The current standard treatment includes surgery or radiotherapy for early stage diseases, while locally advanced cases may require a more aggressive multi-modal approach. Anti-EGFR targeted therapy cetuximab is currently the only approved targeted therapy option, with the recent development of immune-checkpoint inhibitors providing new treatment options.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Giovanni Randon, Rona Yaeger, Jaclyn F. Hechtman, Paolo Manca, Giovanni Fuca, Henry Walch, Jeeyun Lee, Elena Elez, Jenny Seligmann, Benedetta Mussolin, Filippo Pagani, Marco Maria Germani, Margherita Ambrosini, Daniele Rossini, Margherita Ratti, Francesc Salva, Susan D. Richman, Henry Wood, Gouri Nanjangud, Annunziata Gloghini, Massimo Milione, Alberto Bardelli, Filippo de Braud, Federica Morano, Chiara Cremolini, Filippo Pietrantonio
Summary: EGFR amplification is significantly associated with left primary tumor sidedness and RAS/BRAF wild-type status. EGFR-amplified tumors are usually MSS and HER2 nonamplified, with a higher median fraction of genome altered. Patients with EGFR amplification tend to have longer overall survival and better outcomes when exposed to anti-EGFR-based therapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Cell Biology
Yuanzhou Zhang, Shunshun Liang, Bowen Xiao, Jingying Hu, Yechun Pang, Yuling Liu, Juan Yang, Junpin Ao, Lin Wei, Xiaoying Luo
Summary: This study shows that ErbB3/EGFR receptor tyrosine kinase activity is increased in colorectal cancer cells, and miR-323a-3p can directly target both ErbB3 and EGFR, promoting apoptosis in CRC cells. Furthermore, miR-323a-3p acts as a multi-ErbBs inhibitor, enhancing sensitivity to gefitinib and preventing acquired resistance.
CELL DEATH & DISEASE
(2022)
Review
Medicine, General & Internal
Gerardo Rosati, Michele Montrone, Carmen Pacilio, Alfredo Colombo, Giuseppe Cicero, Fernando Paragliola, Angelo Vaia, Luigi Annunziata, Domenico Bilancia
Summary: Although colorectal cancer is increasingly diagnosed in older patients, their representation in clinical trials is insufficient, leading to unclear treatment guidelines. Targeted therapy for elderly patients with wild-type RAS and BRAF is challenging due to potential toxicity. Comprehensive geriatric assessment and recent studies provide important data for differentiating treatment outcomes based on functional status.
JOURNAL OF CLINICAL MEDICINE
(2022)